Exploratory experiment designed to discover new patterns targeting IPCD signature genes in Human patients (TCGA data, pan-cancer immunotherapy dataset). Primary outcome: Immunotherapy response prediction
The researchers used the TIDE (Tumor Immune Dysfunction and Exclusion) algorithm to predict immune response in TCGA ovarian cancer data. They analyzed the relationship between IPCDS scores and immunotherapy response, finding that the low IPCDS group had higher TIDE values, while the no response group had higher IPCDS values. In a pan-cancer immunotherapy dataset, patients in the low IPCDS group demonstrated longer overall survival periods and significant immunotherapy effects. This analysis aimed to establish the clinical utility of the IPCDS model in predicting immunotherapy response in ovarian cancer patients.
TIDE algorithm analysis, correlation analysis between IPCDS scores and therapy response
Low IPCDS scores associated with better immunotherapy response
Significant correlation between IPCDS scores and immunotherapy outcomes
No related hypotheses
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.